Teacher Retirement System of Texas Buys Shares of 400,000 Tempus AI, Inc. (NASDAQ:TEM)

Teacher Retirement System of Texas purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 400,000 shares of the company's stock, valued at approximately $13,504,000. Teacher Retirement System of Texas owned 0.25% of Tempus AI as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of the stock. First Horizon Advisors Inc. purchased a new stake in Tempus AI during the third quarter worth $30,000. Farther Finance Advisors LLC acquired a new position in shares of Tempus AI in the fourth quarter worth about $34,000. FNY Investment Advisers LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth about $67,000. IFP Advisors Inc acquired a new stake in shares of Tempus AI during the 4th quarter valued at about $76,000. Finally, US Bancorp DE acquired a new stake in shares of Tempus AI during the 4th quarter valued at about $80,000. Hedge funds and other institutional investors own 24.22% of the company's stock.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction on Friday, January 31st. The stock was sold at an average price of $60.00, for a total value of $826,200.00. Following the sale, the chief accounting officer now owns 57,237 shares in the company, valued at $3,434,220. The trade was a 19.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jennifer A. Doudna sold 1,320 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $90.00, for a total value of $118,800.00. Following the transaction, the director now owns 36,011 shares of the company's stock, valued at approximately $3,240,990. This represents a 3.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,598,969 shares of company stock worth $317,194,162 in the last ninety days.

Remove Ads

Analysts Set New Price Targets

A number of brokerages have issued reports on TEM. Bank of America increased their price target on Tempus AI from $54.00 to $60.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and upped their price objective for the stock from $50.00 to $55.00 in a research report on Tuesday, February 25th. Loop Capital cut their target price on shares of Tempus AI from $57.00 to $52.00 and set a "buy" rating for the company in a research note on Tuesday, January 14th. TD Cowen reaffirmed a "buy" rating and issued a $74.00 price target (up from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Finally, Wolfe Research downgraded Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Six investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $61.18.

Tempus AI Price Performance

Shares of TEM traded down $0.43 during mid-day trading on Tuesday, reaching $58.57. The stock had a trading volume of 13,545,873 shares, compared to its average volume of 5,108,802. Tempus AI, Inc. has a 52-week low of $22.89 and a 52-week high of $91.45. The business's fifty day moving average is $56.88 and its 200 day moving average is $51.40. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.